Bleeding disorders:
Indications for VONVENDI:
On-demand treatment and control of bleeding episodes in adults with von Willebrand disease (VWD). Perioperative management of bleeding in patients with VWD.
Adult Dosage:
Max infusion rate: 4mL/min. ≥18yrs: Bleeding: give recombinant factor VIII (FVIII) with first infusion if baseline plasma FVIII level <40% or is unknown (see full labeling). Individualize; monitor and adjust according to extent and location of bleed. Minor: initially 40–50 IU/kg, then every 8–24hrs as needed. Major: initially 50–80 IU/kg, then 40–60 IU/kg every 8–24hrs for 2–3 days as needed. Surgery: see full labeling.
Children Dosage:
<18yrs: not established.
VONVENDI Contraindications:
Hypersensitivity to hamster or mouse proteins.
VONVENDI Warnings/Precautions:
Treatment should be supervised by physician. Risk of thromboembolic events in patients with known risk factors or an excessive rise in FVIII levels; monitor, give prophylaxis if clinically indicated. Discontinue immediately if severe allergic reactions occur. Monitor plasma VWF:RCo, FVIII, and inhibitors to VWF and/or FVIII (if suspected). Pregnancy. Nursing mothers.
VONVENDI Classification:
Clotting factor.
Adverse Reactions:
Generalized pruritus, nausea, dizziness; thromboembolic events, antibody formation (consider alternatives).
Generic Drug Availability:
NO
How Supplied:
Single-use vials—1 (w. diluent, supplies)
